NCT00077532 (completed) |
Monoclonal Antibody With or Without gp100 Peptides Plus Montanide ISA-51 in Treating Patients With Stage IV Melanoma |
Melanoma |
National Institutes of Health Clinical Center (CC) National Cancer Institute (NCI) |
Phase 2 |
Peptide-based vaccine (adjuvanted) |
gp100 antigen in incomplete Freund’s adjuvant |
Ipilimumab |
NCT00094653 (completed) |
MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic Melanoma |
Melanoma |
Bristol-Myers Squibb |
Phase 3 |
Peptide-based vaccine (multi-peptide) |
MDX-1379 (gp100) Melanoma Peptide Vaccine |
Ipilimumab |
NCT00084656 (completed) |
Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma |
Melanoma |
Bristol-Myers Squibb National Cancer Institute (NCI) |
Phase 2 |
Peptide-based vaccine (multi-peptide, adjuvanted) |
Tyrosinase/gp100/MART-1 Peptide vaccine in Montanide |
Ipilimumab |
NCT01067287 (ongoing) |
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation |
Myeloma |
Beth Israel Deaconess Medical Center Dana-Farber Cancer Institute Brigham and Women's Hospital Rambam Health Care Campus Gateway for Cancer Research Department of Defense |
Phase 2 |
Dendritic cell-based vaccine (autologous tumour-fused) |
Dendritic Cell/Myeloma Fusion Cell Vaccine with or without CT-011 |
Pidilizumab (CT-011) |
NCT02054520 (ongoing) |
Immunotherapy Study for Patients With Stage IV Melanoma |
Melanoma |
NewLink Genetics Corporation |
Phase 2 |
Tumour cell-based vaccine (allogenic, aGal transfected) |
Hyperacute Melanoma Cancer vaccine Dorgenmeltucel-L |
Ipilimumab |
NCT01096602 (ongoing) |
Blockade of PD-1 in Conjunction With the Dendritic Cell/AML Vaccine Following Chemotherapy Induced Remission |
Leukemia |
Beth Israel Deaconess Medical Center National Institutes of Health (NIH) CureTech Ltd Dana-Farber Cancer Institute |
Phase 2 |
Dendritic cell-based vaccine (autologous tumour-fused) |
Dendritic Cell/AML Fusion Cell Vaccine with or without CT-011 |
Pidilizumab (CT-011) |
NCT01441765 (ongoing) |
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine |
Renal Cell Cancer (RCC) |
Beth Israel Deaconess Medical Center National Institutes of Health (NIH) National Cancer Institute (NCI) Dana-Farber Cancer Institute |
Phase 2 |
Dendritic cell-based vaccine (autologous tumour-fused) |
Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine with or without CT-011 |
Pidilizumab (CT-011) |
NCT01420965 (ongoing) |
Sipuleucel-T, CT-011, and Cyclophosphamide for Advanced Prostate Cancer |
Neoplasm |
Georgia Regents University |
Phase 2 |
Dendritic cell-based vaccine (autologous tumour-pulsed) |
Provenge (Sipuleucel-T/APC8015) + Drug: CT-011 (Anti-PD1 Antibody) |
Pidilizumab (CT-011) |
NCT01896869 (ongoing) |
A Phase 2, Multicenter Study of FOLFIRINOX Followed by Ipilimumab With Allogenic GM-CSF Transfected Pancreatic Tumor Vaccine in the Treatment of Metastatic Pancreatic Cancer |
Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center |
Phase 2 |
Tumour cell-based vaccine (allogenic, GM-CSF transfected) |
GVAX |
Ipilimumab |
NCT02243371 (ongoing) |
GVAX Pancreas Vaccine (With CY) and CRS-207 With or Without Nivolumab |
Pancreatic Cancer |
Sidney Kimmel Comprehensive Cancer Center Bristol-Myers Squibb Stand Up To Cancer Aduro BioTech AACR Research Acceleration Network |
Phase 2 |
Tumour cell-based vaccine (allogenic, GM-CSF transfected), Bacteria-based vaccine (Listeria) |
GVAX |
nivolumab |
NCT00032045 (completed) |
Vaccine Therapy and Monoclonal Antibody Therapy in Treating Patients With Stage IV Melanoma |
Melanoma |
National Cancer Institute (NCI) |
Phase 2 |
Peptide-based vaccine (adjuvanted) |
gp100 antigen incomplete Freund’s adjuvant |
Ipilimumab |
NCT00357461 (withdrawn prior to enrolment)
|
Ipilimumab With or Without Vaccine Therapy in Treating Patients With Previously Treated Stage IV Melanoma
|
Melanoma
|
Bristol-Myers Squibb National Cancer Institute (NCI)
|
Phase 2
|
Peptide-based vaccine (multi-peptide, adjuvanted)
|
gp100:209-217(210M) & gp100:280-288(288V) peptide vaccine in incomplete Freund’s adjuvant
|
Ipilimumab
|